Clinical Trial Update: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating budigalimab and ABBV-382 in adults with HIV, assessing disease activity, adverse events, and pharmacokinetics; the trial status is term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• ABBV-382
• budigalimab (budigalimab)

Snippet

Sponsor: AbbVie | Conditions: Human Immuno-deficiency Virus (HIV) Disease | Phase 2 | Status: TERMINATED